Hi-Tech Pharmaceuticals Expands and Automates Creatine Production

Hi-Tech Pharmaceuticals announced on September 21, 2026, that it is expanding and automating the production capacity of its Phosphagen™ brand creatine monohydrate. The investment aims to address the increasing market demand for high-quality creatine.

The expansion is intended to enhance production processes and ensure a consistent supply chain. Phosphagen™, originally released in 1993 by Experimental and Applied Sciences (EAS), is a well-established creatine product.

Specific financial details of the investment and the timeline for the production upgrades have not yet been disclosed. The company indicated that the enhancements to its manufacturing facility are planned for implementation in the near future.